Valion Bio (VBIO) Stock Price, News & Analysis
What Changed
- Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
- 50 preferred shares come with warrants in Valion Bio (VBIO)'s conditional deal with 3i.
- Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
Price Move History
- Daily moves over 5%
- 52 117 sessions, April 28, 2026 to October 13, 2026
- Largest daily move
- +35.4% close of August 24, 2026
- 1-month change
- -31.4% closing prices, September 11, 2026 to October 13, 2026
Company Description
Valion Bio, Inc. develops immunotherapeutic biologics based on Toll-like receptor 5, or TLR5, activation for cytoprotection and immune modulation. The company, formerly known as Tivic Health Systems, Inc., trades on Nasdaq under the symbol VBIO and operates as a clinical-stage biopharmaceutical company. Its lead program is Entolimod™, a TLR5 agonist being developed for Acute Radiation Syndrome, oncology supportive care, and longevity-related indications.
Entolimod is designed to activate innate immune pathways, including cytoprotective signaling relevant to bone marrow and gastrointestinal tissue preservation after ionizing radiation exposure. The Acute Radiation Syndrome program is positioned as a medical countermeasure for radiological threats, and the company has described FDA Fast Track and Orphan Drug designations for Entolimod in ARS. Valion Bio also links Entolimod's mechanism to oncology supportive care, including potential treatment of neutropenia, a condition commonly associated with chemotherapy, and lymphocyte exhaustion, a state of T-cell dysfunction.
The company's pipeline also includes Entolasta™, a next-generation TLR5 agonist intended to broaden the therapeutic reach of the same innate-immunity platform. Entolasta provides additional pipeline depth in areas that include oncology supportive care and other applications where TLR5-mediated immune modulation may be relevant.
Pipeline and manufacturing model
Valion Bio combines drug development with internal biomanufacturing capabilities through Velocity Bioworks, its wholly owned contract development and manufacturing organization. Velocity Bioworks provides biomanufacturing services to third-party biotechnology companies and also supports Valion Bio's own biologics pipeline. This structure gives the company an operating model that includes clinical-stage therapeutic development and CDMO service activity within the same corporate group.
The company is headquartered in San Antonio, Texas. Its current corporate identity reflects a completed rebranding from Tivic Health Systems to Valion Bio, with the ticker change to VBIO effective in April 2026. The name change marks the company's stated transition from its prior health-technology identity to a biopharmaceutical platform centered on Entolimod, Entolasta, innate immunity, and biologics manufacturing.
Stock Performance
Valion Bio (VBIO) closed at $1.55 on October 13, 2026. Over the past month, the price has lost 31.4%.
VBIO Metrics & Rankings
Price returns through October 13, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Valion Bio has 10 recent news articles, with the latest published 4 days ago. Of the recent coverage, 2 articles coincided with positive price movement and 8 with negative movement. Key topics include management, stock split. View all VBIO news →
SEC Filings
Valion Bio has filed 10 recent SEC filings, including 4 Form 8-K, 2 Form 3, 2 Form 4, 1 Form S-3. The most recent filing was submitted on October 8, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all VBIO SEC filings →
Financial Highlights
operating income reached -$7.9M, and net income was -$8.9M. The company generated -$7.0M in operating cash flow. The current ratio was 20.13, measuring current assets divided by current liabilities.
Upcoming Events
Interim readout
Topline data release
Valion Bio has 2 upcoming scheduled events. The next event, "Interim readout", is scheduled for January 1, 2027 (in 79 days). Investors can track these dates to stay informed about potential catalysts that may affect the VBIO stock price.
Short Interest History
Short interest in Valion Bio (VBIO) currently stands at 88.0 thousand shares, up 128.9% from the previous reporting period, representing 4.5% of the float. Since April 2026, short interest has decreased by 64.2%.
Days to Cover History
Days to cover for Valion Bio (VBIO) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 2.0 days.
VBIO Company Profile & Sector Positioning
Valion Bio (VBIO) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.